INCON EXPERT ARTICLE:

No. 24

'The European Pharma Code and its
impact on Global Medical Meetings'

SEPTEMBER 2015

The European Federation of Pharmaceutical Industries (EFPIA) has agreed a new Disclosure Code which is now impacting the way the pharmaceutical industry interacts with healthcare organisations (HCOs) and individual healthcare professionals (HCPs).

From 2016, the public in Europe will be able to see exactly how much a pharmaceutical company has paid an individual HCP and HCO. With these disclosures set to include all registration, accommodation and travel expenses for medical meetings, meetings planners are concerned about how the new code will affect their events, particularly in terms of HCP attendance.

Here are our top five 'Disclosure Code need-to-knows' for medical meeting planners:

Download article:

Download the PDF (653 kb).

Share this:

AUTHOR:

Simon Dufaur

Global Director, Cardiology & Haematology
Accounts,
MCI Group.

A seasoned healthcare executive, Simon directs MCI’s healthcare team in assisting medical associations and pharmaceutical companies manage increasingly complex regulatory changes and build high-level stakeholder alliances through strategic consulting and service development.

With close to 20 years’ experience in navigating the ever-changing and challenging regulatory environment of the healthcare sector and helping clients to maximise the impact of their face-to-face engagements, today Simon is a highly-skilled expert on healthcare trends and issues affecting the industry. He regularly shares his expertise as a speaker at international conferences and as a guest writer to leading trade magazines.

RELATED LINKS:

SEE OUR PARTNERS: